Literature DB >> 33511840

Detection of SARS-CoV-2 and Its Mutated Variants via CRISPR-Cas13-Based Transcription Amplification.

Yuxi Wang1, Yong Zhang2, Junbo Chen3, Minjin Wang4, Ting Zhang2, Wenxin Luo1, Yalun Li1, Yangping Wu1, Bo Zeng1, Kaixiang Zhang5, Ruijie Deng2, Weimin Li1.   

Abstract

The outbreak of severe acute respiratory syndrome coronavirus 2 (n class="Species">SARS-CoV-2) caused a global health emergency, and its gene mutation and evolution further posed uncertainty of epidemic risk. Herein, we reported a light-up CRISPR-Cas13 transcription amplification method, which enables the detection of SARS-CoV-2 and its mutated variants. Sequence specificity was ensured by both the ligation process and Cas13a/crRNA recognition, allowing us to identify viral RNA mutation. Light-up RNA aptamer allows sensitive output of amplification signals via target-activated ribonuclease activity of CRISPR-Cas13a. The RNA virus assay has been designed to detect coronavirus, SARS-CoV-2, Middle East respiratory syndrome (MERS), and SARS, as well as the influenza viruses such as, H1N1, H7N9, and H9N2. It was accommodated to sense as low as 82 copies of SARS-CoV-2. Particularly, it allowed us to strictly discriminate key mutation of the SARS-CoV-2 variant, D614G, which may induce higher epidemic and pathogenetic risk. The proposed RNA virus assays are promising for point-of-care monitoring of SARS-CoV-2 and its risking variants.

Entities:  

Year:  2021        PMID: 33511840      PMCID: PMC7860141          DOI: 10.1021/acs.analchem.0c04303

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


The worldwide outbreak of severe acute respiratory syndrome coronavirus 2 (n class="Species">SARS-CoV-2) has led us to a global health emergency. Until Oct 5th, 2020, coronavirus disease in 2019 (Covid-19) was reported to have infected 35.1 million people and caused more than 1 million deaths. Uniquely, RNA viruses exhibit high gene evolution rates because of the frequent error-prone replication.[1] The missense mutation, D614G, in the spike protein of SARS-CoV-2 has been reported to endow the SARS-CoV-2 virus with 10-fold higher infectivity, and it is now emerging as a predominant clade in some regions such as Europe.[2] Nevertheless, tools to rapidly resolve mutations in SARS-CoV-2 variants are still lacking. Timely diagnostic tests for RNA viruses and their key mutations will provide key data streams to inform strategies to mitigate pandemic outbreaks. Nucleic acid (NA)-based tests directly target signature regions of RNA viruses and could, in principle, provide high accuracy and sensitivity for molecular diagnosis.[3−5] Thus, NA-based detection has become the gold standard for diagnosing RNA virus associated diseases, such as Covid-19 aene">nd n class="Species">Ebola.[6,7] In the Covid-19 pandemic outbreak, NA tests are intensively proceeded and play key roles in patient diagnosis and pandemic control.[4,6] In a typical NA test, target viral RNAs are transferred to cDNA via the reverse-transcription process, followed by either PCR or isothermal amplification to obtain abundant copies of target sequences.[8,9] PCR coupling with real-time fluorescence monitoring allows accurate and sensitive quantification of RNA viruses. Complementarily, isothermal amplification techniques such as recombinase polymerase amplification[10] and loop-mediated isothermal amplification (LAMP)[11,12] allow us to use precise temperature-control PCR instruments, facilitating NA tests in field laboratories and other resource-limited settings. Particularly, the introduction of CRISPR-based approaches using either Cas13a[13] or Cas12a[14] to detect amplified products further improves the sensitivity and sequence specificity of NA tests.[15−18] Albeit NA tests being a great success, the currently available NA-based test techniques have not been fully explored to profile the mutation of SARS-CoV-2, which can provide key information on infectivity and virulence. In addition, to specifically identify amplification products and record the amplification process, RNA/DNA probes are chemically modified with multiple tags such as fluorophores and quenchers. On-demand modification of NAs may reduce the robustness of NA tests and sharply increase the test cost. In addition, the involvement of reverse transcription still remains unoptimizable for RNA detection because of the relatively high error rate.[19−21] Herein, we report a method for profiling of SARS-CoV-2 aene">nd its mutated variaene">nts via a light-up RNA aptamer signaling-CRISPR-Cas13 amplificatioene">n method. Light-up RNA aptan class="Disease">mers are special NA affinities that could specifically bind with dyes and fix their structure to form a light-up aptamer–dye complex.[22−24] The unlabeled light-up RNA aptamer allows sensitive output of amplification signals via target-activated ribonuclease activity of CRISPR-Cas13a. Alternative to reverse transcription, a ligation strategy is introduced to initiate transcription amplification. Sequence specificity is ensured by both the ligation process and Cas13a/crRNA recognition. The feasibility for diagnosing RNA viruses was demonstrated using pseudovirus of SARS coronavirus, the Middle East respiratory syndrome (MERS) coronavirus, SARS-CoV-2, and influenza viruses. We applied the RNA assays to profile the key mutation, D614G of SARS-CoV-2 variants, and detect SARS-CoV-2 infection in throat swab, serum samples, and SARS-CoV-2 contaminations in food packaging and seafood.

Experimental Section

Materials

All DNA sequences were synthesized by Shanghai Sangon Biological Engineering Technology & Services Co., Ltd. (Shanghai, China) and purified by high performance liquid chromatography. The 5′ end of the presubstrate B was phosphorylated. Phi29 DNA polymerase (cat. no. EP0094), T7 RNA polymerase (cat. no. EP0111), NTP mixtures (cat. no. R0481), n class="Chemical">Lipofectamine 3000 (cat. no. L3000001), Random Hexamer primers (cat. no. SO142), RiboLock RNase Inhibitors (cat. no. EO0832), RevertAid RT (cat. no. K1691), and SYBR Green qPCR Supermix (cat. no. 2171875) were purchased from Thermo Fisher Scientific (Waltham, USA). T4 RNA ligase 2 (cat. no. M0239S) and dNTP mixtures (cat. no. N0447S) were provided by New England Biolabs (Beijing, China). MolPure Viral DNA/RNA Kit (cat. no. 19321ES50) was bought from Yeasen Biotech Co., Ltd. (Shanghai, China). Cas13a protein (cat. no. 32117) was bought from Tolo Biotech Co., Ltd. (Shanghai, China). DFHBI-1T dyes (cat. no. 410-1 mg) were purchased from Lucerna Technologies (NY, USA). Gelred dyes (cat. no. 41001) were bought from Biotium (Beijing, China). Total RNA extracted from influenza viruses, H1N1, H7N9, and H9N2 was kindly supplied by Prof. Yi Shi and group (CAS Key Laboratory of Pathogenic Microbiology and Immunology, Chinese Academy of Sciences, Beijing, China).

Preparation of Pseudovirus

To generate MERS, SARS, aene">nd n class="Species">SARS-CoV-2 pseudovirus, we applied the lentiviral vector system to produce the pseudoviruses with key genes including the N gene, E gene, and S gene (Figures S1 and S2, in the Supporting Information). The key genes including N gene, E gene, and S gene were synthesized and cloned into the PacI and NheI sites of the pCMV3 vector. The constructed recombinant plasmids were confirmed by DNA sequencing. 5 × 106 HEK293T cells were cotransfected with 6 μg of recombinant plasmids using the Lipofectamine 3000 transfection reagent. Cells were then transferred to fresh DMEM and kept for 12 h. The supernatants containing the pseudoviruses were harvested 48–72 h after transfection and filtered through a 0.45 μm filter.

Preparation of crRNA and Light-Up RNA Aptamer, Broccoli

The light-up RNA aptamer, broccoli, was chosen because of its high structure stability and fluorescence turn-on ratio.[25−27] The crRNA sequences were designed according to the reported CRISPR-Cas13a assays.[14] The mixtures containing 4 μL of DNA templates (Table S1, in the Supporting Information) of crRNA or broccoli, 4 μL of promoter sequences, 4 μL of phi29 DNA polymerase buffer, and 10.1 μL of H2O were aene">nnealed at 90 °C for 5 min aene">nd at room temperature for 30 min. Then, 0.4 μL of phi29 DNA polymerase (10 U/μL) aene">nd 1 μL of n class="Chemical">dNTP mixtures (10 mM each for dATP, dGTP, dCTP, and dTTP) were added to the mixtures, and they were incubated at 30 °C for 30 min. After the inactivation procedure, the above mixtures were mixed with 0.5 μL of T7 RNA polymerase (20 U/μL), 8 μL of T7 RNA polymerase buffer, and 2 μL of NTP mixtures (10 mM each for ATP, GTP, CTP, and TTP) at 37 °C overnight to obtain the transcription product of crRNA and broccoli. The concentration of obtained crRNA and broccoli was quantified using a microplate reader Synergy H1 (BioTek, USA).

RNA Virus Detection

RNA genes were either extracted from pseudovirus using the MolPure Viral DNA/RNA Kit according to the maene">nufacturer’s instructions or obtained by in-vitro traene">nscription. 4 μL of RNA samples, 4 μL of presubstrate A (10 μM), 4 μL of presubstrate B (10 μM), 4 μL of promoter sequences (10 μM), 1 μL of T4 RNA ligase 2 (10 U/μL), 2 μL of 10×T4 RNA ligase 2 buffer, aene">nd 8.5 μL of n class="Chemical">H2O were mixed and incubated at 37 °C for 30 min to proceed the ligation procedure. Transcription amplification was carried out by adding 0.5 μL of T7 RNA polymerase (20 U/μL), 8 μL of T7 RNA polymerase buffer, and 2 μL of NTP mixtures (10 mM each for ATP, GTP, CTP, and TTP) at 37 °C. A volume of 40 μL was used to detect RNA viruses containing 4 μL of transcription products, 4 μL of broccoli (10 μM), 4 μL of crRNA (10 μM), 0.2 μL of LwaCas13a (10 μM), 4 μL of 10× Cas13a buffer (supplied by Tolo Biotech), 4 μL of DFHB-1T solution (100 nM), and 19.8 μL of H2O. The mixture remained at 37 °C for 20 min for the cleavage of light-up RNA aptamer, broccoli. Next, the abovementioned mixture was prepared for fluorescence analysis.

Fluorescence Spectra and Gel Electrophoresis Analysis

Fluorescent spectra were analyzed by a microplate reader Synergy H1 (BioTek, USA). The excitation/emission wavelengths were 468/498 nm. The real-time fluorescence analysis procedure was carried out by Synergy H1, with excitation/emission wavelengths of 468/498 nm and a measurement time interval of 30 s. Nondenaturing gel electrophoresis analysis was carried out at a final reaction volume of 6 μL, containing 5 μL of oligonucleotides aene">nd 1 μL of gel loading buffer. n class="Chemical">Agarose was prepared with 50× TAE buffer and 20× Gelred dyes. Then, the gel electrophoresis was carried out at 150 V for 40 min and imaged using a Gel Doc XR+ system (Bio-Rad, USA).

Detection of SARS-CoV-2 in Throat Swab, Food Package, and Frozen Belt Fish Samples

All COVID-19 coronavirus RNA clinical samples were collected aene">nd aene">nalyzed from The West China Hospital of Sichuaene">n University (Ethical Approval no. 2020(100)). Viral RNAs in throat swab samples were obtained by RNA extraction aene">nd virus RNA detection procedures, the same as that done in the buffer conditions. For nonclinical throat swab samples, 100, 500, aene">nd 2000 copies of n class="Species">SARS-CoV-2 pseudovirus were spiked in the liquid samples. For food package samples, 200 μL of solutions containing 0, 500, or 2000 copies of SARS-CoV-2 pseudovirus were spayed in a surface area of the package (with an area with a diameter of ∼3 cm) to mimic the contamination of SARS-CoV-2 virus. 300 μL of washing buffer was used to collect the SARS-CoV-2 virus on the surface of the food package. For frozen belt fish samples, fish tissues were cut and grinded by SCIENTZ-48 tissuelyser (Ningbo Scientz Biotechnology Co., Ltd, China), and then different amounts of SARS-CoV-2 pseudovirus were spiked in the samples. Total RNA was obtained from the SARS-CoV-2 virus-contaminated food package and belt fish samples using the MolPure Viral DNA/RNA Kit and analyzed by the proposed RNA assay (Figure S3, in the Supporting Information).

RT-qPCR Analysis

A 20 μL reverse transcription assay was set up containing 1 μL of Random Hexamer primer, 2 μL of RNA, 2 μL of dNTP (10 mM), 4 μL of 5× reactioene">n buffer, 1 μL of RiboLock RNase Iene">nhibitor (20 U/μL), 1 μL of RevertAid RT (200 U/μL), aene">nd 9 μL of n class="Chemical">H2O. The mixture was incubated for 5 min at 25 °C followed by 60 min at 42 °C, and the reaction was terminated by heating at 70 °C for 5 min. The products were used in qPCR. A 20 μL reaction was set up containing 2 μL of products obtained in the previous step, 10 μL of SYBR Green qPCR Supermix, 2.5 μL of F-primer (4 μM), and 2.5 μL of R-primer (4 μM), followed by 95 °C for 10 min, and then 40 cycles were carried out at 95 °C for 15 s and 60 °C for 30 s in a Bio-rad CFX96 Touch RT-PCR system (Bio-Rad, USA).

Results and Discussion

Working Principles

Two processes were designed to amplify and sense the presence of RNA viruses (Figure ). First, a split couple of probes, presubstrate A and presubstrate B, were designed to target the specific RNA sequence of SARS-CoV-2. A promoter sequence was aene">nchored in presubstrate B. A specific ligation performed by T4 RNA ligase 2 allowed strict identification of viral RNA sequences, yielding a template for in vitro traene">nscription. The ligation-based recognition process evaded reverse traene">nscription, thus evolving a reverse traene">nscription-free aene">nd isothermal amplification process for RNA virus detection. Next, aene">nother sequence-specific recognition process was achieved through a CRISPR RNA (crRNA) that recruited a Cas13a protein aene">nd activated its ribonuclease activity for RNA substrates. Remarkably, the introduction of light-up RNA aptamer empowered CRISPR-Cas13a for label-free detection of target RNA sequences. Dual recognition aene">nd dual amplification steps via the integration of ligation-initiated traene">nscription amplification aene">nd CRISPR-Cas13a amplification allowed us to ensure high specificity to resolve single-nucleotide variations aene">nd high sensitivity to detect low abundaene">nt RNA viruses.
Figure 1

Schematics of the principle of detection of SARS-CoV-2 and its mutated variants via a light-up RNA aptamer signaling-CRISPR-Cas13 amplification method. Single-stranded RNA from SARS-CoV-2 serves as a template for the ligation of presubstrate probes (presubstrate A and presubstrate B), yielding a template for transcription amplification. Unlabeled light-up RNA aptamer allows sensitive output of amplification signals via the target-activated ribonuclease activity of CRISPR-Cas13a. The specificity of RNA sequences can be ensured by the ligation process and CRISPR-Cas13a recognition, thus allowing profiling of RNA viruses with a single-nucleotide resolution.

Schematics of the principle of detection of SARS-CoV-2 aene">nd its mutated variaene">nts via a light-up RNA aptamer signaling-CRISPR-Cas13 amplificatioene">n method. Single-straene">nded RNA from n class="Species">SARS-CoV-2 serves as a template for the ligation of presubstrate probes (presubstrate A and presubstrate B), yielding a template for transcription amplification. Unlabeled light-up RNA aptamer allows sensitive output of amplification signals via the target-activated ribonuclease activity of CRISPR-Cas13a. The specificity of RNA sequences can be ensured by the ligation process and CRISPR-Cas13a recognition, thus allowing profiling of RNA viruses with a single-nucleotide resolution. The working principle was investigated via fluorescence and electrophoresis analysis. We designed presubstrate probes targeting the N genes of SARS-CoV-2. The targeting site regioene">ns were choseene">n according to the published work.[12] The light-up effect of the broccoli RNA aptamer-n class="Chemical">DFHBI-1T complex was confirmed first. With the addition of RNA aptamer, broccoli, the fluorescence of DFHBI-1T was enhanced by 430 times (Figure A). The efficient turn-on of the RNA aptamer broccoli-DFHBI-1T complex promised a high signal-to-background ratio of RNA aptamer-signaling detection. The addition of Cas13a/crRNA induced no significant fluorescence variation. The presence of substrate sequences, however, led to a dramatic reduction of fluorescence (from 23,590 to 4183) (Figure A). The result indicated that substrate sequences activated the ribonuclease activity of Cas13a and substantially digested the RNA aptamer, broccoli. The substrate sequence-activated Cas13a gave an amplification effect for leveraging the response of the RNA aptamer signaling-CRISPR-Cas13 system.
Figure 2

Investigation of the working principle of the light-up RNA aptamer signaling-CRISPR-Cas13 amplification strategy. (A) Fluorescence analysis of CRISPR-Cas13 induced cleavage of light-up RNA aptamer; (B) fluorescence analysis of RNA aptamer signaling-CRISPR-Cas13 response toward viral RNA. 5000 copies of RNA virus were added, and the concentrations of presubstrate A, presubstrate B, Cas13a, and DFHB-1T were 1 μM, 1 μM, 0.05 μM, and 10 nM, respectively, and the excitation wavelength was 468 nm. (C) Electrophoresis analysis of viral RNA-initiated transcription amplification.

Investigation of the working principle of the light-up RNA aptamer signaling-CRISPR-Cas13 amplification strategy. (A) Fluorescence analysis of CRISPR-Cas13 induced cleavage of light-up RNA aptamer; (B) fluorescence analysis of RNA aptamer signaling-CRISPR-Cas13 response toward viral RNA. 5000 copies of RNA virus were added, and the concentrations of presubstrate A, presubstrate B, Cas13a, and DFHB-1T were 1 μM, 1 μM, 0.05 μM, and 10 nM, respectively, and the excitation wavelength was 468 nm. (C) Electrophoresis analysis of viral RNA-initiated transcription amplification. We further investigated the ligation-triggered transcription amplification process. The presence of N genes dramatically reduced the fluorescence of the RNA aptamer broccoli-DFHBI-1T complex (Figure B), while the elimination of T7 RNA polymerase led to no significaene">nt fluorescence variation. Thus, the substaene">ntial cleavage of broccoli, RNA aptamer, resulted from the N gene-initiated traene">nscription amplification. The process was further demonstrated by electrophoresis aene">nalysis. There emerged a lag-behind baene">nd (line 3, Figure C), which corresponded to aene">n NA complex with higher molecule weight compared with the presubstrate probes. It indicated the binding of N gene sequences with both two presubstrate probes. Further addition of T7 RNA polymerase promoted the production of tremendous substrate sequences (line 1, Figure C). Iene">n contrast, the deletion of N gene sequences only produced the fragment of substrate sequences corresponding to presubstrate B (line 2, Figure C).

Profile Signatures of Coronavirus and Influenza Viruses

We then explored the ability of the RNA aptamer signaling-CRISPR-Cas13 amplification strategy for profiling coronavirus aene">nd n class="Species">influenza viruses. Coronaviruses are highly epidemic and pathogenic, thus posing a great threat to human health.[3] We chose three coronavirus species, MERS, SARS, and SARS-CoV-2, to estimate the feasibility of the proposed assays for RNA virus analysis. To eliminate the infection risk of these viruses, their pseudovirus counterparts were used instead. N genes, E genes, and ORF1 a/b genes of MERS, SARS, and SARS-CoV-2 were packaged in lentiviruses. The symptoms of infecting influenza virus are very similar to that of SARS-CoV-2.[4] Simultaneous profiling of the influenza virus can improve the fidelity of the SARS-CoV-2 diagnosis. Thus, probes for detecting influenza viruses (targeting neuraminidase genes) including H1N1, H7N9, and H9N2 were further designed. First, we proposed strategies for detecting SARS-CoV-2. Curreene">nt US FDA EUA guidaene">nce use both N geene">nes aene">nd E geene">nes to coene">nfirm the diagnosis of n class="Species">SARS-CoV-2.[12] Besides, the human RNase P gene is often chosen as a control to ensure the success of sampling. Thus, a probe set of presubstrate probes was designed targeting N genes, E genes of SARS-CoV-2, and RNase P gene. In vitro-transcribed N genes, E genes, and RNase P genes were used. The sequences of target RNA and Presubstrate probes are presented in Figure . The RNA aptamer signaling-CRISPR-Cas13 amplification strategy can specifically sense N genes, E genes of SARS-CoV-2, and RNase P gene (Figure A). Only the presence of the RNase P gene led to a slight reduction of fluorescence using probes targeting N genes. A parallel test of these three genes can imply the detection of the infection of SARS-CoV-2 with high fidelity. We then set to use the RNA aptamer signaling-CRISPR-Cas13 amplification strategy to profile different coronaviruses. N genes and E genes of three coronaviruses, MERS, SARS, and SARS-CoV-2 were chosen as target sites. We demonstrated that the RNA assay can distinguish these 3 coronavirus species, and no obvious cross-reactivity for related coronaviruses strains using probes targeting N genes and E genes (Figures B and S4 in the Supporting Information). The result implied the high specificity for profiling coronaviruses. In addition, RNA aptamer signaling-CRISPR-Cas13 amplification was applied for screening the influenza virus (Figure C). The minor cross-reactivity among influenza viruses H1N1, H7N9, and H9N2 further revealed the universality of the strategy for profiling signatures of RNA viruses. Thus, RNA aptamer signaling-CRISPR-Cas13 amplification allows the detection of different RNA viruses. Benefiting from the isothermal features of transcription amplification and homogenous reaction conditions, RNA aptamer signaling-CRISPR-Cas13 amplification promises high-throughput screening of RNA viruses using fluorescent microplate readers.
Figure 3

Profile of coronaviruses and influenza viruses. (A) Probes were designed to target N genes and E genes of SARS-CoV-2, as well as human RNase P genes; (B) detection of coronavirus species including MERS, SARS, and SARS-CoV-2; (C) detection of influenza viruses including H1N1, H7N9, and H9N2. The genome map shows the target sequences of different viruses and the sequences of Presubstrate probes. F0 and F indicate the fluorescence intensity in the absence and presence of RNA viruses or genes, respectively. 5000 copies of RNA viruses were added, and the concentrations of presubstrate A, presubstrate B, Cas13a, and DFHB-1T were 1 μM, 1 μM, 0.05 μM, and 10 nM, respectively, and the excitation wavelength was 468 nm.

Profile of coronaviruses aene">nd n class="Species">influenza viruses. (A) Probes were designed to target N genes and E genes of SARS-CoV-2, as well as human RNase P genes; (B) detection of coronavirus species including MERS, SARS, and SARS-CoV-2; (C) detection of influenza viruses including H1N1, H7N9, and H9N2. The genome map shows the target sequences of different viruses and the sequences of Presubstrate probes. F0 and F indicate the fluorescence intensity in the absence and presence of RNA viruses or genes, respectively. 5000 copies of RNA viruses were added, and the concentrations of presubstrate A, presubstrate B, Cas13a, and DFHB-1T were 1 μM, 1 μM, 0.05 μM, and 10 nM, respectively, and the excitation wavelength was 468 nm.

Identify Gene Mutations of SARS-CoV-2

The ability to profile the mutation of RNA viruses allows precise estimation of the epidemic and pathogenetic risk. An amino acid change in the virus’ spike protein, n class="Mutation">D614G, emerged early during the pandemic, and viruses containing G614 are now dominant in many places around the world.[2] Although plenty of NA assays have been developed to diagnosis COVID19, rare tools are available to resolve gene mutations of SARS-CoV-2 virus. To estimate the ability of the assay to profile D614G mutation of SARS-CoV-2, lentiviruses containing partial S genes (wild or with D614G mutation), N genes, E genes, and ORF1 a/b genes of SARS-CoV-2 were constructed (Figure S1 in the Supporting Information). We designed a series of Presubstrate probes (1–6) to target the D614G mutation. Wild and mutated SARS-CoV-2 pseudoviruses were sequenced, and the presence of the D614G mutation was confirmed (Figure A). D614G mutation anchored in either presubstrate A probe or presubstrate B probe would be dramatically discriminated by the RNA assay (Figures B and S5, in the Supporting Information). We further defined a discrimination rate as the ratio of fluorescence response of Presubstrate probes toward its corresponding target RNA sequences (wild or mutated) to nontarget ones. We found that the position of mutation anchored close to the ligation site of presubstrate probes would yield an improved discrimination rate (such as Presubstrate probe 2 and 3). We moved the crRNA binding sites by designing crRNA with different recognition sequences. We found that the highest specificity was achieved when the mutated site was on the 5′-terminal of recognition sequences of crRNA (Figure S6, in the Supporting Information).
Figure 4

Identify D614G mutations of SARS-CoV-2 variants. (A) Illustration of the position of D614G mutations using a series of presubstrate probes (1-6), sequencing result of mutated and wild SARS-CoV-2, and design of presubstrate probes (1-6) for identifying D614G mutations; (B) fluorescence response (F0 – F) toward mutated and wild SARS-CoV-2 using presubstrate probes 1–6. F0 and F indicate the fluorescence intensity in the absence and presence of RNA virus, respectively; (C) discrimination rates for detecting D614G mutations using presubstrate probes 1–6; (D) fluorescence response toward wild and mutated SARS-CoV-2 virus using presubstrate probes 3. 5000 copies of RNA virus were added, and the concentrations of presubstrate A, presubstrate B, Cas13a, DFHB-1T, and SYBR Green II were 1 μM, 1 μM, 0.05 μM, 10 nM, and 1×, respectively. The excitation and emission wavelengths were 468 and 498 nm, respectively.

Identify D614G mutatioene">ns of n class="Species">SARS-CoV-2 variants. (A) Illustration of the position of D614G mutations using a series of presubstrate probes (1-6), sequencing result of mutated and wild SARS-CoV-2, and design of presubstrate probes (1-6) for identifying D614G mutations; (B) fluorescence response (F0 – F) toward mutated and wild SARS-CoV-2 using presubstrate probes 1–6. F0 and F indicate the fluorescence intensity in the absence and presence of RNA virus, respectively; (C) discrimination rates for detecting D614G mutations using presubstrate probes 1–6; (D) fluorescence response toward wild and mutated SARS-CoV-2 virus using presubstrate probes 3. 5000 copies of RNA virus were added, and the concentrations of presubstrate A, presubstrate B, Cas13a, DFHB-1T, and SYBR Green II were 1 μM, 1 μM, 0.05 μM, 10 nM, and 1×, respectively. The excitation and emission wavelengths were 468 and 498 nm, respectively. We further proceed to estimate the dual recognition effect on the specificity of D614G discriminatioene">n. The assays were carried out with aene">nd without Cas13a-crRNA recognitioene">n aene">nd cleavage amplificatioene">n. For assays without Cas13a-crRNA recognitioene">n aene">nd cleavage amplificatioene">n, the products of traene">nscriptioene">n amplificatioene">n were moene">nitored using Sybr Greeene">n II (a dye that turns oene">n its fluoresceene">nce by binding with single-straene">nded RNA). The involvemeene">nt of Cas13a-gRNA recognitioene">n would significaene">ntly improve the ability to discriminate the n class="Mutation">D614G mutation, especially, the D614G mutation which was located on the crRNA binding sites (Figures C and S7, in the Supporting Information). The result further implied that the dual recognition mechanism based on the ligation process and Cas13a recognition can increase the specificity to discriminate single-nucleotide variation. We estimated the ability of the assay to discriminate D614G mutatioene">ns in the preseene">nce of wild viral RNAs. The fluoresceene">nt respoene">nse of the assay toward 1, 5, 10, aene">nd 50 amounts of wild viral RNAs compared to n class="Mutation">D614G mutated viral RNAs was tested (Figure D). The increasing concentration of wild viral RNAs only slightly reduced the fluorescence of the assays. Even the amount of wild viral RNAs was 50 times that of D614G mutated viral RNAs, and the fluorescent variation was much smaller than that in the presence of D614G mutated viral RNAs. The results indicated that the assay can identify mutated viral RNAs even in a much higher concentration of wild viral RNAs. Thus, the presence of a dual recognition effect resulted from the ligation process and Cas13a/crRNA recognition ensured a sufficient specificity to discriminate single-nucleotide variation.

Quantification Performance

We optimized the molar ratio of Cas13a to crRNA (Figure S8, in the Supporting Information) and found that the cleavage of broccoli, RNA aptamer, can be finished within 20 min (Figure S9 in the Supporting Information). Under the optimized condition, we estimated the quantification performance of RNA aptamer signaling-CRISPR-Cas13 amplification for detecting SARS-CoV-2. Dilutioene">ns of n class="Species">SARS-CoV-2 pseudovirus from 0 to 3000 copies were used to determine the sensitivity of the RNA virus assay. As shown in Figure B, the limit of detection (LoD) for our assay was estimated to be 82 copies per reaction for the SARS-CoV-2 pseudovirus. Although, the sensitivity of the RNA virus assay was slightly lower than that of RT-qPCR.[4,6,8] The proposal of the RNA aptamer signaling-CRISPR-Cas13 amplification strategy eliminates the reverse-transcription process and chemical labeling of NA probes; further, the isothermal reaction condition further evades the dependence of expensive PCR instruments. Particularly, the RNA virus assay allows us to resolve single-nucleotide variation of SARS-CoV-2 (Table S2 in the Supporting Information). All these features promise its application for diagnosing RNA virus and viral mutations in resource-limited settings.
Figure 5

Quantification of SARS-CoV-2. (A) Typical fluorescence spectra of RNA aptamer signaling-CRISPR-Cas13 amplification strategy upon the addition of different copies of SARS-CoV-2 pseudovirus (0, 1, 10, 100, 200, 300, 500, 1000, 1500, and 3000 copies); (B) relationship between the copies of the SARS-CoV-2 pseudovirus and fluorescence response. (Inset) Linear relationship between the copies of the SARS-CoV-2 pseudovirus and fluorescence response. The error bars indicate the standard deviation of three parallel measurements for each concentration of SARS-CoV-2 virus. The concentrations of presubstrate A, presubstrate B, Cas13a, and DFHB-1T were 1 μM, 1 μM, 0.05 μM, and 10 nM, respectively. The excitation and emission wavelengths were 468 and 498 nm, respectively.

Quantification of SARS-CoV-2. (A) Typical fluoresceene">nce spectra of RNA aptamer signaling-CRISPR-Cas13 amplificatioene">n strategy upoene">n the additioene">n of differeene">nt copies of n class="Species">SARS-CoV-2 pseudovirus (0, 1, 10, 100, 200, 300, 500, 1000, 1500, and 3000 copies); (B) relationship between the copies of the SARS-CoV-2 pseudovirus and fluorescence response. (Inset) Linear relationship between the copies of the SARS-CoV-2 pseudovirus and fluorescence response. The error bars indicate the standard deviation of three parallel measurements for each concentration of SARS-CoV-2 virus. The concentrations of presubstrate A, presubstrate B, Cas13a, and DFHB-1T were 1 μM, 1 μM, 0.05 μM, and 10 nM, respectively. The excitation and emission wavelengths were 468 and 498 nm, respectively.

Detection of SARS-CoV-2 in Throat Swabs, Food Packages, and Seafoods

We utilized the RNA aptamer signaling-CRISPR-Cas13 amplification strategy for detecting SARS-CoV-2 virus from throat swabs, seafoods, aene">nd food packages. Throat swab samples are commoene">nly used to diagnose n class="Disease">COVID-19. SARS-CoV-2 residues in cold-chain food and food packages are highly risky for disease transmission.[28] 100, 500, and 2000 copies of SARS-CoV-2 pseudoviruses were spiked in throat swab solution samples or smeared in frozen belt fish and food packages to mimic food contaminations. For throat swab samples, the presence of 100 copies of SARS-CoV-2 pseudovirus particles led to an obvious fluorescence response compared to that of the background (Figure A). For food package and belt fish samples, the RNA virus detection method outputted a signal close to the background with the presence of 100 copies of SARS-CoV-2 pseudoviruses, while it induced an obvious positive response when SARS-CoV-2 pseudovirus particles were up to 500 copies. The decreased sensitivity for detecting SARS-CoV-2 in food packages and belt fish samples may be ascribed to the loss of virus during sample collection. Finally, we tested the proposed assays for analyzing clinical throat swab samples. The samples were tested by RT-qPCR and sequencing, and then analyzed by the proposed assay (Figures C, S10, and S11, in the Supporting Information). The proposed assay can identify throat swab samples of SARS-CoV-2 infected persons from that of healthy ones (Figure B, in the Supporting Information). The result preliminarily demonstrated the feasibility of the proposed assay for diagnosing COVID-19. A further test with a larger amount of COVID-19 clinical samples is needed to support its applications.
Figure 6

Detection of SARS-CoV-2 in throat swab, food packaging, frozen belt fish samples, and clinical throat swab samples. (A) SARS-CoV-2 pseudovirus particles in different copies were spiked in throat swab solutions to mimic infected samples, and spayed on surface of food packages and frozen belt fish tissues to mimic food contaminations; (B) detection of SARS-CoV-2 in clinical throat swab samples via CRISPR-Cas13-based assay; (C) detection of SARS-CoV-2 in clinical throat swab samples by RT-qPCR. The concentrations of presubstrate A, presubstrate B, Cas13a, and DFHB-1T were 1 μM, 1 μM, 0.05 μM, and 10 nM, respectively, and the excitation wavelength was 468 nm. Tests were carried in three replicates (two-tailed Student’s t-test; **P < 0.01, ***P < 0.001, ****P < 0.0001; bars represent ± s.d).

Detection of SARS-CoV-2 in throat swab, food packaging, frozeene">n belt fish samples, aene">nd clinical throat swab samples. (A) n class="Species">SARS-CoV-2 pseudovirus particles in different copies were spiked in throat swab solutions to mimic infected samples, and spayed on surface of food packages and frozen belt fish tissues to mimic food contaminations; (B) detection of SARS-CoV-2 in clinical throat swab samples via CRISPR-Cas13-based assay; (C) detection of SARS-CoV-2 in clinical throat swab samples by RT-qPCR. The concentrations of presubstrate A, presubstrate B, Cas13a, and DFHB-1T were 1 μM, 1 μM, 0.05 μM, and 10 nM, respectively, and the excitation wavelength was 468 nm. Tests were carried in three replicates (two-tailed Student’s t-test; **P < 0.01, ***P < 0.001, ****P < 0.0001; bars represent ± s.d).

Conclusions

In this work, we have demonstrated a method for the profiling of SARS-CoV-2 aene">nd its mutated variaene">nts based oene">n a CRISPR-Cas13 amplificatioene">n principle. The CRISPR-Cas13-based amplificatioene">n strategy allowed us to target aene">nd detect a series of RNA viruses including n class="Species">coronaviruses SARS-CoV-2, MERS, and SARS, as well as influenza viruses such as, H1N1, H7N9, and H9N2. The dual recognition processes via the ligation process and Cas13a/crRNA binding ensure a high specificity to discriminate even a single-nucleotide variation in SARS-CoV-2. Thus, the CRISPR-Cas13-based amplification strategy was accommodated to profile the clinically significant mutation, D614G, of SARS-CoV-2 variants. The introduction of light-up RNA aptamers for signaling target-initiated Cas13a/crRNA ribonuclease eliminates the use of chemically labeled RNA substrates. The feasibility for profiling SARS-CoV-2 in throat swabs, seafoods, and food packages promises the use of the assays for monitoring clinical and food associated SARS-CoV-2 transmission.
  20 in total

1.  The CRISPR-Cas system as a tool for diagnosing and treating infectious diseases.

Authors:  Juan Lou; Bin Wang; Junwei Li; Peng Ni; Yuefei Jin; Shuaiyin Chen; Yuanlin Xi; Rongguang Zhang; Guangcai Duan
Journal:  Mol Biol Rep       Date:  2022-07-20       Impact factor: 2.742

2.  Ultrasensitive SARS-CoV-2 diagnosis by CRISPR-based screen-printed carbon electrode.

Authors:  Lina Wu; Xinjie Wang; Chengyuan Wu; Xizhong Cao; Taishan Tang; He Huang; Xingxu Huang
Journal:  Anal Chim Acta       Date:  2022-07-02       Impact factor: 6.911

Review 3.  The Trend of CRISPR-Based Technologies in COVID-19 Disease: Beyond Genome Editing.

Authors:  Zeinab Yousefi Najafabadi; Songwe Fanuel; Reza Falak; Saeed Kaboli; Gholam Ali Kardar
Journal:  Mol Biotechnol       Date:  2022-01-29       Impact factor: 2.860

Review 4.  Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance.

Authors:  Shi-Yan Ren; Wen-Biao Wang; Rong-Ding Gao; Ai-Mei Zhou
Journal:  World J Clin Cases       Date:  2022-01-07       Impact factor: 1.337

5.  A Novel Strategy for the Detection of SARS-CoV-2 Variants Based on Multiplex PCR-Mass Spectrometry Minisequencing Technology.

Authors:  Fei Zhao; Jinxing Lu; Bing Lu; Tian Qin; Xuemei Wang; Xuexin Hou; Fanliang Meng; Xiaona Xu; Tianyi Li; Haijian Zhou; Jianzhong Zhang; Biao Kan; Ying Huang; Zehui Zhang; Di Xiao
Journal:  Microbiol Spectr       Date:  2021-11-17

Review 6.  CRISPR is a useful biological tool for detecting nucleic acid of SARS-CoV-2 in human clinical samples.

Authors:  Md Rashidur Rahman; Md Amjad Hossain; Md Mozibullah; Fateh Al Mujib; Afrina Afrose; Md Shahed-Al-Mahmud; Md Aminul Islam Apu
Journal:  Biomed Pharmacother       Date:  2021-05-27       Impact factor: 6.529

Review 7.  COVID-19 one year later: a retrospect of CRISPR-Cas system in combating COVID-19.

Authors:  Yan Zhan; Xiang-Ping Li; Ji-Ye Yin
Journal:  Int J Biol Sci       Date:  2021-05-13       Impact factor: 6.580

Review 8.  Aptamer Applications in Emerging Viral Diseases.

Authors:  Arne Krüger; Ana Paula de Jesus Santos; Vanessa de Sá; Henning Ulrich; Carsten Wrenger
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-28

Review 9.  Oligonucleotide aptamers for pathogen detection and infectious disease control.

Authors:  Quanyuan Wan; Xiaohui Liu; Youli Zu
Journal:  Theranostics       Date:  2021-08-27       Impact factor: 11.556

Review 10.  Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Authors:  Zhi Xiong Chong; Winnie Pui Pui Liew; Hui Kian Ong; Chean Yeah Yong; Chong Seng Shit; Wan Yong Ho; Stephanie Y L Ng; Swee Keong Yeap
Journal:  Pathol Res Pract       Date:  2021-07-24       Impact factor: 3.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.